JPMorgan analyst Chris Schott downgraded Teva Pharmaceuticals (TEVA) to Neutral saying the generic operating environment remains challenging. The analyst does not see fundamentals bottoming until the second half of 2017 at the earliest. Schott highlights the "bearish" generic pricing commentary at his firm's recent healthcare conference as well as Teva's disappointing guidance update. He lowered his price target for Teva shares to $40 from $45. Schott this morning also downgraded Endo International (ENDP) to Neutral. The analyst prefers Mylan (MYL) and Akorn (AKRX) in the Generics space. He keeps Overweight ratings on the two names.